COMP <GO>
CAI vs JNJ // EV/EBITDA & P/E VALUATION
Caris Life Sciences Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CAI 5
— JNJ 8
▲ EV/EBITDA & P/E VALUATION LEADER: JNJ
LAST: $34.33 (-5.01%) • MKT CAP: $10.21B
valuation
95.0x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAI VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CAI | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.40% | 25.50% | -21.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 95.0x | 18.5x | +76.50 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 0.65% | 2.97% | -2.32 | JNJ | /fcf-yield <GO> |
| Operating Margin | 5.60% | 34.70% | -29.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -8.40% | 28.50% | -36.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 97.00% | 6.00% | +91.00 | CAI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.79 | 5.59 | +4.20 | CAI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.20% | -0.60 | CAI | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.8 | 60.4 | +2.43 | CAI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 1.08 | -0.17 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 23.0x | -2.00 | CAI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.21B | $662.49B | -$652.28B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CAI REV | JNJ REV | CAI GROSS % | JNJ GROSS % | CAI FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $812.0M | $94.19B | 44.0% | 67.9% | $66.9M | $19.70B |
| FY 2024 | $412.3M | $88.82B | 44.0% | 69.1% | -$253.6M | $19.84B |
| FY 2023 | $306.1M | $85.16B | 44.0% | 44.0% | -$289.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CAI // BETA 0.91
JNJ // BETA 1.08